Cancalid 2.5, 5, 7.5, 10, 15, 20 & 25 Mg 2,5 mg, 5 mg, 7,5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule
PDF Leaflet Revision Date: 13 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of myelodysplastic syndromes and multiple myeloma.
Dosage (summary)
MDS: 10 mg orally once daily for 21 days in 28-day cycles. MM: 25 mg/day orally for 21 days in 28-day cycles.
Special Populations
- Elderly patients
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; teratogenic risk.
Key Drug Interactions
- Warfarin
- Dexamethasone
- Statins
Contraindications
- Hypersensitivity to lenalidomide
- Pregnancy
- Lactation
Common side effects
- Neutropenia
- Thrombocytopenia
- Fatigue
- Diarrhea
Counselling Points
- Use effective contraception during treatment.
- Regular pregnancy testing for women of childbearing potential.
- Monitor for signs of bleeding and infection.
Serious warnings
- Severe birth defects
- Venous thromboembolism
- Myocardial infarction
Important Disclaimer
The Cancalid 2.5, 5, 7.5, 10, 15, 20 & 25 Mg 2,5 mg, 5 mg, 7,5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule professional information leaflet below is the property of Aurogen Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
